Achieving a successful pregnancy in women with polycystic ovary syndrome

Endocrinology and Metabolism Clinics of North America

Volumn 40, Issue 4, 2011, Pages 865-894

  Araki, Takako ^a   Elias, Rony ^b   Rosenwaks, Zev ^b   Poretsky, Leonid ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Infertility; Polycystic ovary syndrome (PCOS); Pregnancy

Indexed keywords

ANASTROZOLE; ANTIANDROGEN; AROMATASE INHIBITOR; CHORIONIC GONADOTROPIN; CLOMIFENE; CLOMIFENE CITRATE; CYPROTERONE ACETATE; EXENDIN 4; FINASTERIDE; FOLLITROPIN; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCOCORTICOID; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADOTROPIN; LETROZOLE; METFORMIN; ORAL CONTRACEPTIVE AGENT; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SPIRONOLACTONE; THIAZOLIDINE DERIVATIVE; TROGLITAZONE;

ACNE; BIRTH WEIGHT; CLINICAL FEATURE; DRUG DOSE INCREASE; DRUG MECHANISM; DRUG MEGADOSE; EXERCISE; FEMALE INFERTILITY; FERTILIZATION IN VITRO; GYNECOLOGIC SURGERY; HIRSUTISM; HUMAN; LIFESTYLE MODIFICATION; LIVER TOXICITY; LOW DRUG DOSE; MATERNAL HYPERTENSION; METABOLIC DISORDER; MULTIPLE CYCLE TREATMENT; MULTIPLE PREGNANCY; NONHUMAN; OVARY HYPERSTIMULATION; OVARY POLYCYSTIC DISEASE; PATHOGENESIS; PERINATAL CARE; PREECLAMPSIA; PREGNANCY; PREGNANCY DIABETES MELLITUS; PREGNANCY OUTCOME; PREVALENCE; PRIORITY JOURNAL; PROGENY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; SPONTANEOUS ABORTION; WEIGHT GAIN; WEIGHT REDUCTION;

ABORTION, SPONTANEOUS; ADULT; DIET; EXERCISE; FEMALE; FERTILIZATION IN VITRO; HUMANS; HYPERANDROGENISM; INFANT, NEWBORN; INFERTILITY, FEMALE; INSULIN RESISTANCE; MALE; OVULATION INDUCTION; POLYCYSTIC OVARY SYNDROME; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; WEIGHT LOSS;

EID: 82855161020     PISSN: 08898529     EISSN: 15584410     Source Type: Journal    
DOI: 10.1016/j.ecl.2011.08.003     Document Type: Review

References (211)

1. Stein I.F., Leventhal M.L. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935, 29:181.
2. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004, 81:19.
3. Azziz R., Carmina E., Dewailly D., et al. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 2006, 91:4237.
4. Azziz R., Woods K.S., Reyna R., et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004, 89:2745.
5. Moll E., van der Veen F., van Wely M. The role of metformin in polycystic ovary syndrome: a systematic review. Hum Reprod Update 2007, 13:527.
6. Franks S. Polycystic ovary syndrome. N Engl J Med 1995, 333:853.
7. Knochenhauer E.S., Key T.J., Kahsar-Miller M., et al. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 1998, 83:3078.
8. Ehrmann D.A. Polycystic ovary syndrome. N Engl J Med 2005, 352:1223.
9. Patel S.S., Carr B.R. Oocyte quality in adult polycystic ovary syndrome. Semin Reprod Med 2008, 26:196.
10. Pasquali R., Pelusi C., Genghini S., et al. Obesity and reproductive disorders in women. Hum Reprod Update 2003, 9:359.
11. Lake J.K., Power C., Cole T.J. Women's reproductive health: the role of body mass index in early and adult life. Int J Obes Relat Metab Disord 1997, 21:432.
12. Rich-Edwards J.W., Goldman M.B., Willett W.C., et al. Adolescent body mass index and infertility caused by ovulatory disorder. Am J Obstet Gynecol 1994, 171:171.
13. Dunaif A., Segal K.R., Futterweit W., et al. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989, 38:1165.
14. Dunaif A. Hyperandrogenic anovulation (PCOS): a unique disorder of insulin action associated with an increased risk of non-insulin-dependent diabetes mellitus. Am J Med 1995, 98:33S.
15. Legro R.S. Polycystic ovary syndrome. Long term sequelae and management. Minerva Ginecol 2002, 54:97.
16. Peppard H.R., Marfori J., Iuorno M.J., et al. Prevalence of polycystic ovary syndrome among premenopausal women with type 2 diabetes. Diabetes Care 2001, 24:1050.
17. Seto-Young D., Paliou M., Schlosser J., et al. Direct thiazolidinedione action in the human ovary: insulin-independent and insulin-sensitizing effects on steroidogenesis and insulin-like growth factor binding protein-1 production. J Clin Endocrinol Metab 2005, 90:6099.
18. Poretsky L., Grigorescu F., Seibel M., et al. Distribution and characterization of insulin and insulin-like growth factor I receptors in normal human ovary. J Clin Endocrinol Metab 1985, 61:728.
19. Poretsky L., Cataldo N.A., Rosenwaks Z., et al. The insulin-related ovarian regulatory system in health and disease. Endocr Rev 1999, 20:535.
20. Poretsky L. Polycystic ovary syndrome. Principles of diabetes mellitus 2010, 701. Springer Verlag, New York, Chapter 4. 2nd edition.
21. Maciel G.A., Soares Junior J.M., Alves da Motta E.L., et al. Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin. Fertil Steril 2004, 81:355.
22. Nestler J.E. Regulation of the aromatase activity of human placental cytotrophoblasts by insulin, insulin-like growth factor-I, and -II. J Steroid Biochem Mol Biol 1993, 44:449.
23. Burcelin R., Thorens B., Glauser M., et al. Gonadotropin-releasing hormone secretion from hypothalamic neurons: stimulation by insulin and potentiation by leptin. Endocrinology 2003, 144:4484.
24. Poretsky L., Clemons J., Bogovich K. Hyperinsulinemia and human chorionic gonadotropin synergistically promote the growth of ovarian follicular cysts in rats. Metabolism 1992, 41:903.
25. Moret M., Stettler R., Rodieux F., et al. Insulin modulation of luteinizing hormone secretion in normal female volunteers and lean polycystic ovary syndrome patients. Neuroendocrinology 2009, 89:131.
26. Rosenfield R.L., Bordini B. Evidence that obesity and androgens have independent and opposing effects on gonadotropin production from puberty to maturity. Brain Res 2010, 1364:186-197.
27. Jain A., Polotsky A.J., Rochester D., et al. Pulsatile luteinizing hormone amplitude and progesterone metabolite excretion are reduced in obese women. J Clin Endocrinol Metab 2007, 92:2468.
28. Poretsky L., Kalin M.F. The gonadotropic function of insulin. Endocr Rev 1987, 8:132.
29. Berga S.L., Daniels T.L. Can polycystic ovary syndrome exist without concomitant hypothalamic dysfunction?. Semin Reprod Endocrinol 1997, 15:169.
30. Berga S.L., Guzick D.S., Winters S.J. Increased luteinizing hormone and alpha-subunit secretion in women with hyperandrogenic anovulation. J Clin Endocrinol Metab 1993, 77:895.
31. Morales A.J., Laughlin G.A., Butzow T., et al. Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features. J Clin Endocrinol Metab 1996, 81:2854.
32. Venturoli S., Porcu E., Fabbri R., et al. Episodic pulsatile secretion of FSH, LH, prolactin, oestradiol, oestrone, and LH circadian variations in polycystic ovary syndrome. Clin Endocrinol (Oxf) 1988, 28:93.
33. Barnes R.B., Rosenfield R.L., Burstein S., et al. Pituitary-ovarian responses to nafarelin testing in the polycystic ovary syndrome. N Engl J Med 1989, 320:559.
34. Erickson G.F., Magoffin D.A., Garzo V.G., et al. Granulosa cells of polycystic ovaries: are they normal or abnormal?. Hum Reprod 1992, 7:293.
35. Gilling-Smith C., Story H., Rogers V., et al. Evidence for a primary abnormality of thecal cell steroidogenesis in the polycystic ovary syndrome. Clin Endocrinol (Oxf) 1997, 47:93.
36. Ibanez L., Hall J.E., Potau N., et al. Ovarian 17-hydroxyprogesterone hyperresponsiveness to gonadotropin-releasing hormone (GnRH) agonist challenge in women with polycystic ovary syndrome is not mediated by luteinizing hormone hypersecretion: evidence from GnRH agonist and human chorionic gonadotropin stimulation testing. J Clin Endocrinol Metab 1996, 81:4103.
37. Pierro E., Andreani C.L., Lazzarin N., et al. Further evidence of increased aromatase activity in granulosa luteal cells from polycystic ovary. Hum Reprod 1997, 12:1890.
38. Ibanez L., Potau N., Virdis R., et al. Postpubertal outcome in girls diagnosed of premature pubarche during childhood: increased frequency of functional ovarian hyperandrogenism. J Clin Endocrinol Metab 1993, 76:1599.
39. Ibanez L., Potau N., Zampolli M., et al. Girls diagnosed with premature pubarche show an exaggerated ovarian androgen synthesis from the early stages of puberty: evidence from gonadotropin-releasing hormone agonist testing. Fertil Steril 1997, 67:849.
40. Oppenheimer E., Linder B., DiMartino-Nardi J. Decreased insulin sensitivity in prepubertal girls with premature adrenarche and acanthosis nigricans. J Clin Endocrinol Metab 1995, 80:614.
41. Poretsky L., Piper B. Insulin resistance, hypersecretion of LH, and a dual-defect hypothesis for the pathogenesis of polycystic ovary syndrome. Obstet Gynecol 1994, 84:613.
42. Abbott D.H., Barnett D.K., Bruns C.M., et al. Androgen excess fetal programming of female reproduction: a developmental aetiology for polycystic ovary syndrome?. Hum Reprod Update 2005, 11:357.
43. Barker D.J. Fetal programming of coronary heart disease. Trends Endocrinol Metab 2002, 13:364.
44. Givens J.R. Familial polycystic ovarian disease. Endocrinol Metab Clin North Am 1988, 17:771.
45. Hague W.M., Adams J., Reeders S.T., et al. Familial polycystic ovaries: a genetic disease?. Clin Endocrinol (Oxf) 1988, 29:593.
46. Legro R.S., Driscoll D., Strauss J.F., et al. Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc Natl Acad Sci U S A 1998, 95:14956.
47. Wood J.R., Dumesic D.A., Abbott D.H., et al. Molecular abnormalities in oocytes from women with polycystic ovary syndrome revealed by microarray analysis. J Clin Endocrinol Metab 2007, 92:705.
48. Azziz R., Bradley E.L., Potter H.D., et al. Chronic hyperinsulinemia and the adrenal androgen response to acute corticotropin-(1-24) stimulation in hyperandrogenic women. Am J Obstet Gynecol 1995, 172:1251.
49. Goldzieher J.W., Green J.A. The polycystic ovary. I. Clinical and histologic features. J Clin Endocrinol Metab 1962, 22:325.
50. Hull M.G. Epidemiology of infertility and polycystic ovarian disease: endocrinological and demographic studies. Gynecol Endocrinol 1987, 1:235.
51. Teede H., Deeks A., Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med 2010, 8:41.
52. Yen Reproductive endocrinology 1991, Saunders, Philadelphia, p. 593. 3rd edition.
53. Clark A.M., Thornley B., Tomlinson L., et al. Weight loss in obese infertile women results in improvement in reproductive outcome for all forms of fertility treatment. Hum Reprod 1998, 13:1502.
54. Hollmann M., Runnebaum B., Gerhard I. Effects of weight loss on the hormonal profile in obese, infertile women. Hum Reprod 1996, 11:1884.
55. Huber-Buchholz M.M., Carey D.G., Norman R.J. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. J Clin Endocrinol Metab 1999, 84:1470.
56. Moran L.J., Brinkworth G., Noakes M., et al. Effects of lifestyle modification in polycystic ovarian syndrome. Reprod Biomed Online 2006, 12:569.
57. Kiddy D.S., Hamilton-Fairley D., Bush A., et al. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 1992, 36:105.
58. Homburg R. The management of infertility associated with polycystic ovary syndrome. Reprod Biol Endocrinol 2003, 1:109.
59. Hamilton-Fairley D., Kiddy D., Anyaoku V., et al. Response of sex hormone binding globulin and insulin-like growth factor binding protein-1 to an oral glucose tolerance test in obese women with polycystic ovary syndrome before and after calorie restriction. Clin Endocrinol (Oxf) 1993, 39:363.
60. Pettigrew R., Hamilton-Fairley D. Obesity and female reproductive function. Br Med Bull 1997, 53:341.
61. Clark A.M., Ledger W., Galletly C., et al. Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women. Hum Reprod 1995, 10:2705.
62. Hoeger K.M., Kochman L., Wixom N., et al. A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertil Steril 2004, 82:421.
63. Jacobsen D.J., Donnelly J.E., Snyder-Heelan K., et al. Adherence and attrition with intermittent and continuous exercise in overweight women. Int J Sports Med 2003, 24:459.
64. Greenblatt R.B., Jullien M. Concours Med 1965, 87:1401. [in French].
65. Yildiz B.O., Chang W., Azziz R. Polycystic ovary syndrome and ovulation induction. Minerva Ginecol 2003, 55:425.
66. Zain M.M., Jamaluddin R., Ibrahim A., et al. Comparison of clomiphene citrate, metformin, or the combination of both for first-line ovulation induction, achievement of pregnancy, and live birth in Asian women with polycystic ovary syndrome: a randomized controlled trial. Fertil Steril 2009, 91:514.
67. Gorlitsky G.A., Kase N.G., Speroff L. Ovulation and pregnancy rates with clomiphene citrate. Obstet Gynecol 1978, 51:265.
68. Imani B., Eijkemans M.J., te Velde E.R., et al. Predictors of patients remaining anovulatory during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. J Clin Endocrinol Metab 1998, 83:2361.
69. Imani B., Eijkemans M.J., te Velde E.R., et al. Predictors of chances to conceive in ovulatory patients during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. J Clin Endocrinol Metab 1999, 84:1617.
70. Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group Consensus on infertility treatment related to polycystic ovary syndrome. Hum Reprod 2008, 23:462.
71. Speroff L. Clinical gynecologic endocrinology and infertility 2005, Lippincott Williams & Wilkins, Philadelphia, p. 1180. 7th edition.
72. Nestler J.E., Stovall D., Akhter N., et al. Strategies for the use of insulin-sensitizing drugs to treat infertility in women with polycystic ovary syndrome. Fertil Steril 2002, 77:209.
73. Butzow T.L., Kettel L.M., Yen S.S. Clomiphene citrate reduces serum insulin-like growth factor I and increases sex hormone-binding globulin levels in women with polycystic ovary syndrome. Fertil Steril 1995, 63:1200.
74. Nestler J.E., Jakubowicz D.J., Evans W.S., et al. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 1998, 338:1876.
75. Gonen Y., Casper R.F. Sonographic determination of a possible adverse effect of clomiphene citrate on endometrial growth. Hum Reprod 1990, 5:670.
76. Brzechffa P.R., Daneshmand S., Buyalos R.P. Sequential clomiphene citrate and human menopausal gonadotrophin with intrauterine insemination: the effect of patient age on clinical outcome. Hum Reprod 1998, 13:2110.
77. Wang C.F., Gemzell C. The use of human gonadotropins for the induction of ovulation in women with polycystic ovarian disease. Fertil Steril 1980, 33:479.
78. White D.M., Polson D.W., Kiddy D., et al. Induction of ovulation with low-dose gonadotropins in polycystic ovary syndrome: an analysis of 109 pregnancies in 225 women. J Clin Endocrinol Metab 1996, 81:3821.
79. Christin-Maitre S., Hugues J.N. A comparative randomized multicentric study comparing the step-up versus step-down protocol in polycystic ovary syndrome. Hum Reprod 2003, 18:1626.
80. De Leo V., la Marca A., Ditto A., et al. Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome. Fertil Steril 1999, 72:282.
81. Yarali H., Yildiz B.O., Demirol A., et al. Co-administration of metformin during rFSH treatment in patients with clomiphene citrate-resistant polycystic ovarian syndrome: a prospective randomized trial. Hum Reprod 2002, 17:289.
82. Fleming R., Haxton M.J., Hamilton M.P., et al. Successful treatment of infertile women with oligomenorrhoea using a combination of an LHRH agonist and exogenous gonadotrophins. Br J Obstet Gynaecol 1985, 92:369.
83. European and Middle East Orgalutran Study Group Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. Hum Reprod 2001, 16:644.
84. Barmat L.I., Chantilis S.J., Hurst B.S., et al. A randomized prospective trial comparing gonadotropin-releasing hormone (GnRH) antagonist/recombinant follicle-stimulating hormone (rFSH) versus GnRH-agonist/rFSH in women pretreated with oral contraceptives before in vitro fertilization. Fertil Steril 2005, 83:321.
85. Legro R.S., Barnhart H.X., Schlaff W.D., et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med 2007, 356:551.
86. Velazquez E.M., Mendoza S., Hamer T., et al. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 1994, 43:647.
87. Ng E.H., Wat N.M., Ho P.C. Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene-resistant polycystic ovaries: a randomized, double-blinded placebo-controlled trial. Hum Reprod 2001, 16:1625.
88. Ning J., Clemmons D.R. AMP-activated protein kinase inhibits IGF-I signaling and protein synthesis in vascular smooth muscle cells via stimulation of insulin receptor substrate 1 S794 and tuberous sclerosis 2 S1345 phosphorylation. Mol Endocrinol 2010, 24:1218.
89. Nestler J.E., Jakubowicz D.J. Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 1996, 335:617.
90. Stadtmauer L.A., Toma S.K., Riehl R.M., et al. Metformin treatment of patients with polycystic ovary syndrome undergoing in vitro fertilization improves outcomes and is associated with modulation of the insulin-like growth factors. Fertil Steril 2001, 75:505.
91. Palomba S., Orio F., Falbo A., et al. Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005, 90:4068.
92. Neveu N., Granger L., St-Michel P., et al. Comparison of clomiphene citrate, metformin, or the combination of both for first-line ovulation induction and achievement of pregnancy in 154 women with polycystic ovary syndrome. Fertil Steril 2007, 87:113.
93. Moll E., Bossuyt P.M., Korevaar J.C., et al. Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. BMJ 2006, 332:1485.
94. Creanga A.A., Bradley H.M., McCormick C., et al. Use of metformin in polycystic ovary syndrome: a metaanalysis. Obstet Gynecol 2008, 111:959.
95. Imani B., Eijkemans M.J., te Velde E.R., et al. A nomogram to predict the probability of live birth after clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. Fertil Steril 2002, 77:91.
96. Rausch M.E., Legro R.S., Barnhart H.X., et al. Predictors of pregnancy in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2009, 94:3458.
97. Nader S. Reproductive endocrinology: live birth prediction in polycystic ovary syndrome. Nat Rev Endocrinol 2010, 6:64.
98. Coetzee E.J., Jackson W.P. Metformin in management of pregnant insulin-independent diabetics. Diabetologia 1979, 16:241.
99. Dunaif A., Scott D., Finegood D., et al. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab 1996, 81:3299.
100. Mitwally M.F., Kuscu N.K., Yalcinkaya T.M. High ovulatory rates with use of troglitazone in clomiphene-resistant women with polycystic ovary syndrome. Hum Reprod 1999, 14:2700.
101. Azziz R., Ehrmann D., Legro R.S., et al. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab 2001, 86:1626.
102. Belli S.H., Graffigna M.N., Oneto A., et al. Effect of rosiglitazone on insulin resistance, growth factors, and reproductive disturbances in women with polycystic ovary syndrome. Fertil Steril 2004, 81:624.
103. Glueck C.J., Moreira A., Goldenberg N., et al. Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin. Hum Reprod 2003, 18:1618.
104. Nissen S.E., Wolski K. Rosiglitazone revisited: an updated metaanalysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 2010, 170(14):1191-1201.
105. Komar C.M., Braissant O., Wahli W., et al. Expression and localization of PPARs in the rat ovary during follicular development and the periovulatory period. Endocrinology 2001, 142:4831.
106. Seto-Young D., Avtanski D., Strizhevsky M., et al. Interactions among peroxisome proliferator activated receptor-gamma, insulin signaling pathways, and steroidogenic acute regulatory protein in human ovarian cells. J Clin Endocrinol Metab 2007, 92:2232.
107. Gasic S., Nagamani M., Green A., et al. Troglitazone is a competitive inhibitor of 3beta-hydroxysteroid dehydrogenase enzyme in the ovary. Am J Obstet Gynecol 2001, 184:575.
108. Mu Y.M., Yanase T., Nishi Y., et al. Insulin sensitizer, troglitazone, directly inhibits aromatase activity in human ovarian granulosa cells. Biochem Biophys Res Commun 2000, 271:710.
109. DeFronzo R.A., Ratner R.E., Han J., et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005, 28:1092.
110. Gama R., Norris F., Wright J., et al. The entero-insular axis in polycystic ovarian syndrome. Ann Clin Biochem 1996, 33(Pt 3):190.
111. Vrbikova J., Hill M., Bendlova B., et al. Incretin levels in polycystic ovary syndrome. Eur J Endocrinol 2008, 159:121.
112. Vilsboll T., Krarup T., Deacon C.F., et al. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001, 50:609.
113. MacLusky N.J., Cook S., Scrocchi L., et al. Neuroendocrine function and response to stress in mice with complete disruption of glucagon-like peptide-1 receptor signaling. Endocrinology 2000, 141:752.
114. Jeibmann A., Zahedi S., Simoni M., et al. Glucagon-like peptide-1 reduces the pulsatile component of testosterone secretion in healthy males. Eur J Clin Invest 2005, 35:565.
115. Elkind-Hirsch K., Marrioneaux O., Bhushan M., et al. Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab 2008, 93:2670.
116. Mitwally M.F., Casper R.F. Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. Fertil Steril 2001, 75:305.
117. Sher G., Keskintepe L., Keskintepe M., et al. Genetic analysis of human embryos by metaphase comparative genomic hybridization (mCGH) improves efficiency of IVF by increasing embryo implantation rate and reducing multiple pregnancies and spontaneous miscarriages. Fertil Steril 2009, 92:1886.
118. Badawy A., Abdel Aal I., Abulatta M. Clomiphene citrate or anastrozole for ovulation induction in women with polycystic ovary syndrome? A prospective controlled trial. Fertil Steril 2009, 92:860.
119. Health Canada endorsed important safety information on Femara (letrozole) [letter]. 2005. Available at: Accessed August 2, 2011. http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/public/_2005/femara_pc-cp-eng.php.
120. Daly D.C., Walters C.A., Soto-Albors C.E., et al. A randomized study of dexamethasone in ovulation induction with clomiphene citrate. Fertil Steril 1984, 41:844.
121. Evron S., Navot D., Laufer N., et al. Induction of ovulation with combined human gonadotropins and dexamethasone in women with polycystic ovarian disease. Fertil Steril 1983, 40:183.
122. Lobo R.A., Paul W., March C.M., et al. Clomiphene and dexamethasone in women unresponsive to clomiphene alone. Obstet Gynecol 1982, 60:497.
123. Bider D., Amoday I., Tur-Kaspa I., et al. The addition of a glucocorticoid to the protocol of programmed oocyte retrieval for in-vitro fertilization-a randomized study. Hum Reprod 1996, 11:1606.
124. Rein M.S., Jackson K.V., Sable D.B., et al. Dexamethasone during ovulation induction for in-vitro fertilization: a pilot study. Hum Reprod 1996, 11:253.
125. Fitzgerald C., Elstein M., Spona J. Effect of age on the response of the hypothalamo-pituitary-ovarian axis to a combined oral contraceptive. Fertil Steril 1999, 71:1079.
126. Martin K.A., Chang R.J., Ehrmann D.A., et al. Evaluation and treatment of hirsutism in premenopausal women: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008, 93:1105.
127. Swiglo B.A., Cosma M., Flynn D.N., et al. Clinical review: antiandrogens for the treatment of hirsutism: a systematic review and metaanalyses of randomized controlled trials. J Clin Endocrinol Metab 2008, 93:1153.
128. Townsend K.A., Marlowe K.F. Relative safety and efficacy of finasteride for treatment of hirsutism. Ann Pharmacother 2004, 38:1070.
129. Armar N.A., McGarrigle H.H., Honour J., et al. Laparoscopic ovarian diathermy in the management of anovulatory infertility in women with polycystic ovaries: endocrine changes and clinical outcome. Fertil Steril 1990, 53:45.
130. Gurgan T., Kisnisci H., Yarali H., et al. Evaluation of adhesion formation after laparoscopic treatment of polycystic ovarian disease. Fertil Steril 1991, 56:1176.
131. Eijkemans M.J., Polinder S., Mulders A.G., et al. Individualized cost-effective conventional ovulation induction treatment in normogonadotrophic anovulatory infertility (WHO group 2). Hum Reprod 2005, 20:2830.
132. Damario M.A., Barmat L., Liu H.C., et al. Dual suppression with oral contraceptives and gonadotrophin releasing-hormone agonists improves in-vitro fertilization outcome in high responder patients. Hum Reprod 1997, 12:2359.
133. Lainas T.G., Sfontouris I.A., Zorzovilis I.Z., et al. Flexible GnRH antagonist protocol versus GnRH agonist long protocol in patients with polycystic ovary syndrome treated for IVF: a prospective randomised controlled trial (RCT). Hum Reprod 2010, 25:683.
134. Mulders A.G., Laven J.S., Imani B., et al. IVF outcome in anovulatory infertility (WHO group 2)-including polycystic ovary syndrome-following previous unsuccessful ovulation induction. Reprod Biomed Online 2003, 7:50.
135. Sengoku K., Tamate K., Takuma N., et al. The chromosomal normality of unfertilized oocytes from patients with polycystic ovarian syndrome. Hum Reprod 1997, 12:474.
136. Kodama H., Fukuda J., Karube H., et al. High incidence of embryo transfer cancellations in patients with polycystic ovarian syndrome. Hum Reprod 1995, 10:1962.
137. Lin Y.H., Seow K.M., Hsieh B.C., et al. Application of GnRH antagonist in combination with clomiphene citrate and hMG for patients with exaggerated ovarian response in previous IVF/ICSI cycles. J Assist Reprod Genet 2007, 24:331.
138. Heijnen E.M., Eijkemans M.J., Hughes E.G., et al. A metaanalysis of outcomes of conventional IVF in women with polycystic ovary syndrome. Hum Reprod Update 2006, 12:13.
139. Kdous M., Chaker A., Bouyahia M., et al. Tunis Med 2009, 87:834. [in French].
140. Engmann L., DiLuigi A., Schmidt D., et al. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertil Steril 2008, 89:84.
141. Griesinger G., Diedrich K., Tarlatzis B.C., et al. GnRH-antagonists in ovarian stimulation for IVF in patients with poor response to gonadotrophins, polycystic ovary syndrome, and risk of ovarian hyperstimulation: a metaanalysis. Reprod Biomed Online 2006, 13:628.
142. Tso L.O., Costello M.F., Albuquerque L.E., et al. Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. Cochrane Database Syst Rev 2009, 2. CD006105.
143. Dale P.O., Tanbo T., Abyholm T. In-vitro fertilization in infertile women with the polycystic ovarian syndrome. Hum Reprod 1991, 6:238.
144. Gonen Y., Balakier H., Powell W., et al. Use of gonadotropin-releasing hormone agonist to trigger follicular maturation for in vitro fertilization. J Clin Endocrinol Metab 1990, 71:918.
145. Chian R.C., Buckett W.M., Tulandi T., et al. Prospective randomized study of human chorionic gonadotrophin priming before immature oocyte retrieval from unstimulated women with polycystic ovarian syndrome. Hum Reprod 2000, 15:165.
146. Chian R.C. In-vitro maturation of immature oocytes for infertile women with PCOS. Reprod Biomed Online 2004, 8:547.
147. Lin Y.H., Hwang J.L., Huang L.W., et al. Combination of FSH priming and hCG priming for in-vitro maturation of human oocytes. Hum Reprod 2003, 18:1632.
148. Siristatidis C.S., Maheshwari A., Bhattacharya S. In vitro maturation in sub fertile women with polycystic ovarian syndrome undergoing assisted reproduction. Cochrane Database Syst Rev 2009, 1. CD006606.
149. Homburg R., Armar N.A., Eshel A., et al. Influence of serum luteinising hormone concentrations on ovulation, conception, and early pregnancy loss in polycystic ovary syndrome. BMJ 1988, 297:1024.
150. Jakubowicz D.J., Iuorno M.J., Jakubowicz S., et al. Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. J Clin Endocrinol Metab 2002, 87:524.
151. Sagle M., Bishop K., Ridley N., et al. Recurrent early miscarriage and polycystic ovaries. BMJ 1988, 297:1027.
152. Fedorcsak P., Storeng R., Dale P.O., et al. Obesity is a risk factor for early pregnancy loss after IVF or ICSI. Acta Obstet Gynecol Scand 2000, 79:43.
153. Atiomo W.U., Bates S.A., Condon J.E., et al. The plasminogen activator system in women with polycystic ovary syndrome. Fertil Steril 1998, 69:236.
154. Jakubowicz D.J., Seppala M., Jakubowicz S., et al. Insulin reduction with metformin increases luteal phase serum glycodelin and insulin-like growth factor-binding protein 1 concentrations and enhances uterine vascularity and blood flow in the polycystic ovary syndrome. J Clin Endocrinol Metab 2001, 86:1126.
155. Clifford K., Rai R., Watson H., et al. Does suppressing luteinising hormone secretion reduce the miscarriage rate? Results of a randomised controlled trial. BMJ 1996, 312:1508.
156. Glueck C.J., Phillips H., Cameron D., et al. Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study. Fertil Steril 2001, 75:46.
157. Holte J., Gennarelli G., Wide L., et al. High prevalence of polycystic ovaries and associated clinical, endocrine, and metabolic features in women with previous gestational diabetes mellitus. J Clin Endocrinol Metab 1998, 83:1143.
158. Mikola M., Hiilesmaa V., Halttunen M., et al. Obstetric outcome in women with polycystic ovarian syndrome. Hum Reprod 2001, 16:226.
159. Radon P.A., McMahon M.J., Meyer W.R. Impaired glucose tolerance in pregnant women with polycystic ovary syndrome. Obstet Gynecol 1999, 94:194.
160. Haakova L., Cibula D., Rezabek K., et al. Pregnancy outcome in women with PCOS and in controls matched by age and weight. Hum Reprod 2003, 18:1438.
161. Urman B., Sarac E., Dogan L., et al. Pregnancy in infertile PCOD patients. Complications and outcome. J Reprod Med 1997, 42:501.
162. Boomsma C.M., Eijkemans M.J., Hughes E.G., et al. A metaanalysis of pregnancy outcomes in women with polycystic ovary syndrome. Hum Reprod Update 2006, 12:673.
163. Toulis K.A., Goulis D.G., Kolibianakis E.M., et al. Risk of gestational diabetes mellitus in women with polycystic ovary syndrome: a systematic review and a metaanalysis. Fertil Steril 2009, 92:667.
164. Chu S.Y., Abe K., Hall L.R., et al. Gestational diabetes mellitus: all Asians are not alike. Prev Med 2009, 49:265.
165. Glueck C.J., Wang P., Kobayashi S., et al. Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome. Fertil Steril 2002, 77:520.
166. Nawaz F.H., Khalid R., Naru T., et al. Does continuous use of metformin throughout pregnancy improve pregnancy outcomes in women with polycystic ovarian syndrome?. J Obstet Gynaecol Res 2008, 34:832.
167. Seely E.W., Solomon C.G. Insulin resistance and its potential role in pregnancy-induced hypertension. J Clin Endocrinol Metab 2003, 88:2393.
168. Steegers E.A., von Dadelszen P., Duvekot J.J., et al. Pre-eclampsia. Lancet 2010, 376:631.
169. Diamant Y.Z., Rimon E., Evron S. High incidence of preeclamptic toxemia in patients with polycystic ovarian disease. Eur J Obstet Gynecol Reprod Biol 1982, 14:199.
170. Gjonnaess H. The course and outcome of pregnancy after ovarian electrocautery in women with polycystic ovarian syndrome: the influence of body-weight. Br J Obstet Gynaecol 1989, 96:714.
171. de Vries M.J., Dekker G.A., Schoemaker J. Higher risk of preeclampsia in the polycystic ovary syndrome. A case control study. Eur J Obstet Gynecol Reprod Biol 1998, 76:91.
172. Hamasaki T., Yasuhi I., Hirai M., et al. Hyperinsulinemia increases the risk of gestational hypertension. Int J Gynaecol Obstet 1996, 55:141.
173. Rowe J.W., Young J.B., Minaker K.L., et al. Effect of insulin and glucose infusions on sympathetic nervous system activity in normal man. Diabetes 1981, 30:219.
174. Fridstrom M., Nisell H., Sjoblom P., et al. Are women with polycystic ovary syndrome at an increased risk of pregnancy-induced hypertension and/or preeclampsia?. Hypertens Pregnancy 1999, 18:73.
175. Hales C.N., Barker D.J. The thrifty phenotype hypothesis. Br Med Bull 2001, 60:5.
176. Silverman B.L., Rizzo T.A., Cho N.H., et al. Long-term effects of the intrauterine environment. The Northwestern University Diabetes in Pregnancy Center. Diabetes Care 1998, 21(Suppl 2):B142.
177. Legro R.S., Roller R.L., Dodson W.C., et al. Associations of birthweight and gestational age with reproductive and metabolic phenotypes in women with polycystic ovarian syndrome and their first-degree relatives. J Clin Endocrinol Metab 2010, 95:789.
178. Recabarren S.E., Padmanabhan V., Codner E., et al. Postnatal developmental consequences of altered insulin sensitivity in female sheep treated prenatally with testosterone. Am J Physiol Endocrinol Metab 2005, 289:E801.
179. Ibanez L., Jaramillo A., Enriquez G., et al. Polycystic ovaries after precocious pubarche: relation to prenatal growth. Hum Reprod 2007, 22:395.
180. Ibanez L., Jimenez R., de Zegher F. Early puberty-menarche after precocious pubarche: relation to prenatal growth. Pediatrics 2006, 117:117.
181. Sir-Petermann T., Hitchsfeld C., Maliqueo M., et al. Birth weight in offspring of mothers with polycystic ovarian syndrome. Hum Reprod 2005, 20:2122.
182. Crosignani P.G., Nicolosi A.E. Polycystic ovarian disease: heritability and heterogeneity. Hum Reprod Update 2001, 7:3.
183. Kahsar-Miller M.D., Nixon C., Boots L.R., et al. Prevalence of polycystic ovary syndrome (PCOS) in first-degree relatives of patients with PCOS. Fertil Steril 2001, 75:53.
184. Sir-Petermann T., Codner E., Perez V., et al. Metabolic and reproductive features before and during puberty in daughters of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2009, 94:1923.
185. Recabarren S.E., Smith R., Rios R., et al. Metabolic profile in sons of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2008, 93:1820.
186. Sir-Petermann T., Maliqueo M., Codner E., et al. Early metabolic derangements in daughters of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2007, 92:4637.
187. Eisner J.R., Dumesic D.A., Kemnitz J.W., et al. Timing of prenatal androgen excess determines differential impairment in insulin secretion and action in adult female rhesus monkeys. J Clin Endocrinol Metab 2000, 85:1206.
188. Eisner J.R., Dumesic D.A., Kemnitz J.W., et al. Increased adiposity in female rhesus monkeys exposed to androgen excess during early gestation. Obes Res 2003, 11:279.
189. Bruns C.M., Baum S.T., Colman R.J., et al. Insulin resistance and impaired insulin secretion in prenatally androgenized male rhesus monkeys. J Clin Endocrinol Metab 2004, 89:6218.
190. Norman R.J., Masters S., Hague W. Hyperinsulinemia is common in family members of women with polycystic ovary syndrome. Fertil Steril 1996, 66:942.
191. Urbanek M., Legro R.S., Driscoll D.A., et al. Thirty-seven candidate genes for polycystic ovary syndrome: strongest evidence for linkage is with follistatin. Proc Natl Acad Sci U S A 1999, 96:8573.
192. Tucci S., Futterweit W., Concepcion E.S., et al. Evidence for association of polycystic ovary syndrome in Caucasian women with a marker at the insulin receptor gene locus. J Clin Endocrinol Metab 2001, 86:446.
193. Ehrmann D.A., Tang X., Yoshiuchi I., et al. Relationship of insulin receptor substrate-1 and -2 genotypes to phenotypic features of polycystic ovary syndrome. J Clin Endocrinol Metab 2002, 87:4297.
194. Ehrmann D.A., Schwarz P.E., Hara M., et al. Relationship of calpain-10 genotype to phenotypic features of polycystic ovary syndrome. J Clin Endocrinol Metab 2002, 87:1669.
195. Gonzalez A., Abril E., Roca A., et al. Specific CAPN10 gene haplotypes influence the clinical profile of polycystic ovary patients. J Clin Endocrinol Metab 2003, 88:5529.
196. Hara M., Alcoser S.Y., Qaadir A., et al. Insulin resistance is attenuated in women with polycystic ovary syndrome with the Pro(12)Ala polymorphism in the PPARgamma gene. J Clin Endocrinol Metab 2002, 87:772.
197. Yilmaz M., Ergun M.A., Karakoc A., et al. Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma gene in women with polycystic ovary syndrome. Gynecol Endocrinol 2006, 22:336.
198. Ewens K.G., Stewart D.R., Ankener W., et al. Family-based analysis of candidate genes for polycystic ovary syndrome. J Clin Endocrinol Metab 2010, 95:2306.
199. Eyvazzadeh A.D., Pennington K.P., Pop-Busui R., et al. The role of the endogenous opioid system in polycystic ovary syndrome. Fertil Steril 2009, 92:1.
200. Hickey T., Chandy A., Norman R.J. The androgen receptor CAG repeat polymorphism and X-chromosome inactivation in Australian Caucasian women with infertility related to polycystic ovary syndrome. J Clin Endocrinol Metab 2002, 87:161.
201. Goodarzi M.O., Xu N., Cui J., et al. Small glutamine-rich tetratricopeptide repeat-containing protein alpha (SGTA), a candidate gene for polycystic ovary syndrome. Hum Reprod 2008, 23:1214.
202. Diamanti-Kandarakis E., Bartzis M.I., Zapanti E.D., et al. Polymorphism T-->C (-34 bp) of gene CYP17 promoter in Greek patients with polycystic ovary syndrome. Fertil Steril 1999, 71:431.
203. Gaasenbeek M., Powell B.L., Sovio U., et al. Large-scale analysis of the relationship between CYP11A promoter variation, polycystic ovarian syndrome, and serum testosterone. J Clin Endocrinol Metab 2004, 89:2408.
204. Gharani N., Waterworth D.M., Batty S., et al. Association of the steroid synthesis gene CYP11a with polycystic ovary syndrome and hyperandrogenism. Hum Mol Genet 1997, 6:397.
205. Cousin P., Calemard-Michel L., Lejeune H., et al. Influence of SHBG gene pentanucleotide TAAAA repeat and D327N polymorphism on serum sex hormone-binding globulin concentration in hirsute women. J Clin Endocrinol Metab 2004, 89:917.
206. Xita N., Tsatsoulis A., Chatzikyriakidou A., et al. Association of the (TAAAA)n repeat polymorphism in the sex hormone-binding globulin (SHBG) gene with polycystic ovary syndrome and relation to SHBG serum levels. J Clin Endocrinol Metab 2003, 88:5976.
207. Goodarzi M.O., Maher J.F., Cui J., et al. FEM1A and FEM1B: novel candidate genes for polycystic ovary syndrome. Hum Reprod 2008, 23:2842.
208. Maher J.F., Hines R.S., Futterweit W., et al. FEM1A is a candidate gene for polycystic ovary syndrome. Gynecol Endocrinol 2005, 21:330.
209. Prodoehl M.J., Hatzirodos N., Irving-Rodgers H.F., et al. Genetic and gene expression analyses of the polycystic ovary syndrome candidate gene fibrillin-3 and other fibrillin family members in human ovaries. Mol Hum Reprod 2009, 15:829.
210. Urbanek M., Sam S., Legro R.S., et al. Identification of a polycystic ovary syndrome susceptibility variant in fibrillin-3 and association with a metabolic phenotype. J Clin Endocrinol Metab 2007, 92:4191.
211. Urbanek M., Woodroffe A., Ewens K.G., et al. Candidate gene region for polycystic ovary syndrome on chromosome 19p13.2. J Clin Endocrinol Metab 2005, 90:6623.